bioMérieux Seeks FDA Clearance for Updated Gastrointestinal Testing Panels
The new molecular panels are designed to detect up to 22 pathogens in one hour with enhanced norovirus detection.
bioMérieux Seeks FDA Authorization for Point-of-Care Vaginitis Test
The automated PCR test provides results in 20 minutes to help clinicians diagnose common causes of vaginitis during a patient visit.
bioMérieux Celebrates New Regional Headquarters in Riyadh, Saudi Arabia
bioMérieux Celebrates New Regional Headquarters in Riyadh, Saudi Arabia
Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis
Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis
bioMérieux invests in Allergen Alert, a startup resulting from its intrapreneurship program
bioMérieux has just acquired a stake in Allergen Alert, an innovative startup specializing in the rapid detection of food allergens for individuals and professionals.
Altesa BioSciences and bioMérieux Announce Collaboration for Altesa’s Upcoming Phase 2B COPD Clinical Trial
Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE® SPOTFIRE® point-of-care diagnostics platform at U.S. sites.
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux Recognized as Top 1% by S&P Global
bioMérieux Recognized as Top 1% by S&P Global
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance
BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance
UTAH REPS. CURTIS AND MOORE TOUR BIOMERIEUX
Representatives John Curtis (R-UT) and Blake Moore (R-UT) toured bioMérieux.
Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance
Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance
